Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients

Area of Science:

• Oncology
• Cardiology
• Biomarker Discovery

Background:

• Cardiotoxicity is a significant concern for breast cancer patients undergoing anthracycline-trastuzumab therapy.
• Chemotherapy-related cardiac dysfunction (CRCD) affects 3-36% of patients, often necessitating treatment cessation.
• Current CRCD detection methods like echocardiography and troponin measurements are not always timely, cost-effective, or accessible.

Purpose of the Study:

• To propose a novel panel of serum biomarkers for the early and accurate detection of CRCD.
• To enable early intervention, maximizing chemotherapy benefits and minimizing cardiac damage.
• To provide a cost-effective and easily implementable solution for CRCD screening, especially in resource-limited settings.

Main Methods:

• Literature review to identify potential serum biomarkers.
• Proposed panel includes topoisomerase 2β, troponin T/I, myeloperoxidase, NT-proBNP, and specific microRNAs (miR-208b, miR-34a, miR-150).
• Focus on detecting CRCD before clinical symptoms or echocardiographic evidence of dysfunction.

Main Results:

• The proposed biomarker panel offers potential for enhanced specificity and sensitivity in CRCD detection.
• Early identification of CRCD can be achieved prior to overt cardiotoxicity.
• The panel is designed for ease of implementation and cost-effectiveness.

Conclusions:

• A multi-biomarker panel holds promise for early CRCD detection in breast cancer patients.
• This approach could significantly improve patient outcomes by allowing continued chemotherapy and mitigating cardiac risks.
• Further clinical validation is needed to establish the panel's efficacy in diverse healthcare settings.